5.18 to 5.25 USD billion (company guidance)
Dexcom guided to 2026 revenue of $5.18 to $5.25 billion, in its second-quarter 2026 release.
Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1)1.308 USD billion
Dexcom's second-quarter 2026 revenue was $1.308 billion, up 13% year over year, with US revenue up 11%.
Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1)2.0 USD billion
Abbott's worldwide continuous glucose monitor sales were $2.0 billion in the fourth quarter of 2025, up 15.0% on a reported basis.
Abbott (SEC Form 8-K, Exhibit 99.1)Why this market is moving now
- The FDA cleared the first over-the-counter CGM on March 5, 2024, opening the market to adults not using insulin.
- Dexcom guides to $5.18 to $5.25 billion of revenue in 2026.
- About 40.1 million Americans had diabetes in 2023.
Key figures
Each figure links to the page it came from.
| Figure | Value | Year | Source |
|---|---|---|---|
| Dexcom's full-year 2025 revenue was $4.662 billion, up 16%. | 4.662 USD billion | 2025 | Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1) |
| Dexcom guided to 2026 revenue of $5.18 to $5.25 billion, in its second-quarter 2026 release. | 5.18 to 5.25 USD billion (company guidance) | 2026 | Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1) |
| Dexcom's second-quarter 2026 revenue was $1.308 billion, up 13% year over year, with US revenue up 11%. | 1.308 USD billion | 2026 | Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1) |
| Abbott's worldwide continuous glucose monitor sales were $2.0 billion in the fourth quarter of 2025, up 15.0% on a reported basis. | 2.0 USD billion | 2025 | Abbott (SEC Form 8-K, Exhibit 99.1) |
| Abbott's continuous glucose monitor sales grew 7.3% on a reported basis in the third quarter of 2026. | 7.3 % growth | 2026 | Abbott (SEC Form 8-K, Exhibit 99.1) |
| The FDA cleared the first over-the-counter continuous glucose monitor, Dexcom's Stelo, on March 5, 2024, for adults 18 and older who do not use insulin. | March 5, 2024 clearance date | 2024 | U.S. Food and Drug Administration |
| An estimated 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023, or 12.0% of the population. | 40.1 million people | 2023 | CDC |
| An estimated 115.2 million US adults aged 18 or older had prediabetes. | 115.2 million adults | 2023 | CDC |
Companies to watch
Dexcom
Maker of Stelo and Dexcom G-series CGMs; full-year 2025 revenue was $4.662 billion.
Abbott
Maker of FreeStyle Libre; worldwide CGM sales were $2.0 billion in Q4 2025.
What the full report covers
- 1
Executive summary
The answer on two pages: size, growth and what drives it.
- 2
Market size and outlook
History, the current year and a five-year view with base, low and high cases.
- 3
Segments and regions
Splits by product, buyer and geography across the US, Europe and MEA.
- 4
Company profiles
The main players, how they compete and where they are investing.
- 5
Data and method
Every figure in Excel, with the sources and assumptions behind it.
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the United States market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is Dexcom?
Dexcom reported full-year 2025 revenue of $4.662 billion, up 16%, in its February 12, 2026 results release filed with the SEC.
How much does Abbott earn from CGMs?
Abbott reported worldwide continuous glucose monitor sales of $2.0 billion in Q4 2025, and 7.3% growth in Q3 2026.
Are there over-the-counter CGMs?
Yes. The FDA cleared Dexcom's Stelo as the first over-the-counter CGM on March 5, 2024, for adults 18 and older who do not use insulin.
How many Americans have diabetes?
The CDC estimates 40.1 million people in the US had diagnosed or undiagnosed diabetes in 2023, and 115.2 million adults had prediabetes.
What is Dexcom guiding for 2026?
Dexcom's July 30, 2026 release lists 2026 revenue guidance of $5.18 to $5.25 billion, about 11-13% growth. This is company guidance.
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1): Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results (2026-02-12)
Full year revenue grew 16% versus the prior year to $4.662 billion on a reported basis
- Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1): Dexcom Reports Second Quarter 2026 Financial Results (2026-07-30)
Revenue of $5.18 - $5.25 billion (approximately 11-13% growth).
- Dexcom, Inc. (SEC Form 8-K, Exhibit 99.1): Dexcom Reports Second Quarter 2026 Financial Results (2026-07-30)
Revenue grew 13% year-over-year to $1.308 billion on a reported basis.
- Abbott (SEC Form 8-K, Exhibit 99.1): Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook (2026-01-22)
sales of continuous glucose monitors were $2.0 billion and grew 15.0 percent on a reported basis.
- Abbott (SEC Form 8-K, Exhibit 99.1): Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance (2026-10-21)
sales of continuous glucose monitors grew 7.3 percent on a reported basis
- U.S. Food and Drug Administration: FDA Clears First Over-the-Counter Continuous Glucose Monitor (2024-03-05)
intended for anyone 18 years and older who does not use insulin.
- CDC: National Diabetes Statistics Report (2026-09-16)
40.1 million
- CDC: National Diabetes Statistics Report (2026-09-16)
115.2 million
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline